In a strategic move to broaden capabilities and extend geographical reach, it was announced today that AxTalis, a Belgium based consultancy firm supporting Biopharma and Medtech companies in Regulatory Affairs, Market Access and Medical Affairs across the Benelux region, has joined forces with MAP Patient Access.
The move is backed by private equity firm Kester Capital whose investment in 2023 in MAP paved the way for this first bolt on acquisition.
This marks a significant milestone for the new group, as it strengthens the company’s position in mainland Europe, with the aim of delivering a joined up, comprehensive portfolio of services. By combining AxTalis’s geographical footprint and services alongside MAP Patient Access’s proprietary membership platform and specialist consultancy expertise the group is well poised to offer enhanced services to a wider range of Biopharma and Medtech companies. These will include an expanded and improved membership offering with broader digital capabilities, supported by the companies’ well-established consultancy expertise.
“We are thrilled to join forces with the team at AxTalis,” said Steve Glass, Group CEO. “This strategic move aligns perfectly with our mission to accelerate access to treatments for even more patients across a wider geographical area. With the EU HTA on the horizon, this acquisition is an important step to build our pan-European presence and support our clients in an ever-changing landscape. AxTalis brings a wealth of experience and complementary services to our group, furthering our ambition to offer our clients a fully integrated and multi-disciplinary solution that goes beyond geographical boundaries.”
“We are excited to become part of the Group”, said Sven Tops and Frank Vanderdonck, co-founders and Managing Partners at AxTalis. “This acquisition opens up new opportunities for us to deliver even greater value to our clients. Together, we will continue to drive positive change and broaden access to therapeutic solutions through collaboration with physicians, researchers, companies, health authorities and patients.”
Adam Maidment, Managing Partner at Kester Capital, said: “We are delighted to be supporting MAP on its growth journey, and the addition of AxTalis represents an important step for the new group as it continues to expand internationally and offer a greater breadth of services to its clients. We are looking forward to partnering with Frank and Sven alongside the existing MAP leadership team to continue the growth of the combined business organically and through further acquisitions.”
For more information about MAP Patient Access, visit www.mappatientaccess.com. For more information on AxTalis, visit www.axtalis.com. You can find out more about Kester Capital by visiting www.kestercapital.com.
Notes to Editors
Advisers to the transaction:
Buy-side:
Osborne Clarke (legal)
Grant Thornton (financial and tax)
Towergate (insurance)
Sell-side:
Mazars (M&A advisory, legal)
